Related Experiment Videos
Long-term treatment of subjects with borderline glucose tolerance
Advances in Experimental Medicine and Biology
|January 1, 1979
Insights
Individuals with borderline glucose tolerance face increased cardiovascular risks. Tolbutamide treatment appears to lower risks of diabetes progression and cardiovascular events, without evidence of harm.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Borderline glucose tolerance is associated with elevated cardiovascular disease (CVD) risk compared to normal glucose tolerance.
- Understanding interventions for individuals with impaired glucose metabolism is crucial for public health.
Purpose of the Study:
- To evaluate the impact of tolbutamide treatment on cardiovascular morbidity and mortality in subjects with borderline glucose tolerance.
- To assess the effect of tolbutamide on the progression to overt diabetes.
Main Methods:
- Observational data analysis focusing on cardiovascular events and diabetes progression.
- Comparison of outcomes between tolbutamide-treated and untreated subjects with borderline glucose tolerance.
Main Results:
- Tolbutamide treatment was associated with a reduction in cardiovascular morbidity and mortality.
- Data suggests tolbutamide may reduce the progression to overt diabetes.
Conclusions:
- Tolbutamide treatment may offer cardiovascular benefits for individuals with borderline glucose tolerance.
- Current data does not support the hypothesis that tolbutamide exacerbates cardiovascular damage.
Abstract:
Subjects with borderline glucose tolerance are at a higher risk of suffering and dying from cardiovascular disease than subjects with normal glucose tolerance. Our data on the progression to overt diabetes and our data on cardiovascular morbidity and mortality suggests that tolbutamide treatment reduces these risks. In any case, we have no data supporting the theory that tolbutamide promotes cardiovascular damage.